BlackRock Discloses Passive Stake in Olema Pharmaceuticals
Ticker: OLMA · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1750284
| Field | Detail |
|---|---|
| Company | Olema Pharmaceuticals, INC. (OLMA) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a big, passive stake in Olema Pharma, a bullish signal for the stock.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). This filing indicates BlackRock's passive ownership of Olema's Common Stock, signaling their belief in the company's long-term prospects without seeking to influence management. For investors, this means a large, reputable institution sees value in Olema, potentially adding a layer of confidence to the stock.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant, passive stake in Olema Pharmaceuticals, which can be a vote of confidence for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by signaling institutional confidence.
Analyst Insight
A smart investor would view BlackRock's passive stake as a positive signal, suggesting institutional confidence in Olema Pharmaceuticals, and might consider further research into the company's fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Olema Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its passive stake in Olema Pharmaceuticals for the foreseeable future. (BlackRock Inc.) — high confidence, target: 2025-01-29
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the 'reporting person' in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742 and located at 50 Hudson Yards, New York, NY 10001.
What company's securities are the subject of this filing?
The subject company is Olema Pharmaceuticals, Inc., identified by CIK 0001750284, with its business address at 780 Brannan Street, San Francisco, CA 94103.
What is the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement is December 31, 2023.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock of Olema Pharmaceuticals, Inc. is 68062P106.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding Olema Pharmaceuticals, Inc. (OLMA).